MDL 2409: In Re: Nexium (Esomeprazole) Antitrust Litigation
LEAD CASE NUMBER 1:11-md-2242
These actions are purported nationwide class actions alleging that defendants violated federal and state antitrust laws by excluding generic competition for Nexium through, among other things, entering into reverse payment agreements in which AstraZeneca allegedly agreed to pay the generic manufacturer defendants substantial sums in exchange for delaying entry of their less expensive generic versions of Nexium into the market. These cases have been assigned to Judge William G. Young.
To view the docket entries, they can click here.
To view the Liason Counsel information, they can click here.
To view the Opinions, they can click here.